Drugs / Enterobacterium capsules
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06563934 | Aug 2024 → May 2026 overdue | liver cancer | Xu Yong, MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06563947 | Aug 2024 → May 2026 overdue | liver cancer | Xu Yong, MD | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enterobacterium capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06563947 ↗ |
| Route | Oral | “orally 6 capsules/day for 10 consecutive days” NCT06563934 ↗ |